A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer
Status:
Active, not recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to compare the objective response rate (ORR) of high
dose cemiplimab (HDREGN2810) and standard dose cemiplimab plus ipilimumab combination therapy
(SDREGN2810/ipi) to the ORR of standard dose cemiplimab (SDREGN2810) in the second-line
treatment of patients with advanced squamous or non-squamous non-small cell lung cancer
(NSCLC), in patients whose tumors express programmed cell death ligand 1 (PD-L1) in <50% of
tumor cells.